A2

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

WIPO

PCT

162162

(43) International publication date
12 April 2001 (12.04.2001)

(10) International publication number
WO 01/25210 A2

(51) International patent classification[7]: C07D 213/85, A61K 31/4418, 31/4427, C07D 401/12, 405/12, 409/12, 413/12, 417/12

(21) International application number: PCT/EP00/09153

(22) International filing date:
19 September 2000 (19.09.2000)

(25) Language of filing: German

G00002

(26) Language of publication: German

(30) Data relating to the priority:
199 47 154.1 1 October 1999 (01.10.1999) DE

(71) Applicant *(for all designated States except US)*: BAYER AKTIENGESELLSCHAFT [DE/DE]; 51368 Leverkusen (DE).

(72) Inventors; and

(75) Inventors/Applicants *(US only)*: ROSENTRETER, Ulrich [DE/DE]; Obere Rutenbeck 6, 42349 Wuppertal (DE). HENNING, Rolf [DE/DE]; Am Jagdhaus 115, 42113 Wuppertal (DE). BAUSER, Marcus [DE/DE]; Heinrich-Bammel-Weg 40, 42327 Wuppertal (DE). KRÄMER, Thomas [DE/DE]; Schneewittchenweg 37, 42111 Wuppertal (DE). VAUPEL, Andrea [DE/DE]; Birkenhöhe 9, 42113 Wuppertal (DE). HÜBSCH, Walter [DE/DE]; Wildsteig 22, 42113 Wuppertal (DE). DEMBOWSKY, Klaus [DE/US]; 289 Shawmut Avenue, Boston, MA 02116 (US). SALCHER-SCHRAUF-STÄTTER, Olga [DE/DE]; Bremer Str. 28, 42109 Wuppertal (DE). STASCH, Johannes-Peter [DE/DE]; Alfred-Nobel-Str. 109, 42651 Solingen (DE). KRAHN, Thomas [DE/DE]; Wiener Str. 29, 58135 Hagen (DE). PERZBORN, Elisabeth [DE/DE]; Am Tescher Busch 13, 42327 Wuppertal (DE).

(74) Joint Representative: BAYER AKTIENGESELLSCHAFT; 51368 Leverkusen (DE).

(81) Designated states *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated states *(regional)*: ARIPO Patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


Published:
- *Without the International Search Report and to be republished once the report has been received*

For an explanation of the two-letter codes and the other abbreviations, reference is made to the explanations ("Guidance Notes on Codes and Abbreviations") at the beginning of each regular edition of the PCT Gazette.

As printed

(54) Title: SUBSTITUTED 2-THIO-3,5-DICYANO-4-ARYL-6-AMINOPYRIDINES AND THE USE THEREOF

(54) Bezeichnung: SUBSTITUIERTE 2-THIO-3,5-DICYANO-4-ARYL-6-AMINOPYRIDINE UND IHRE VERWENDUNG



(I)

(57) Abstract: The invention relates to compounds of general formula (I), a method for the production thereof and the use thereof as pharmacologically effective substances for a broad medical indication spectrum. Furthermore, selective adenosine receptor ligands, preferably selective adenosine A1-, adenosine A2a- and/or adenosine A2b-receptor ligands are provided for the prophylaxis and/or the treatment of diseases, especially cardiovascular diseases, diseases of the urogenital region, diseases of the respiratory tract, inflammatory and neuroinflammatory diseases, diabetes, especially pancreatic diabetes, neurodegenerative diseases, pain states, cancer as well as liver fibrosis and liver cirrhosis.

(57) Zusammenfassung: Es werden Verbindungen der allgemeinen Formel (I) beschrieben, ein Verfahren zu ihrer Herstellung sowie ihre Verwendung als pharmakologisch wirksame Substanzen für ein breites medizinisches Indikationsspektrum. Des weiteren werden selektive Adenosin-Rezeptorliganden, vorzugsweise selektive Adenosin-A1-, Adenosin-A2a- und/oder Adenosin-A2b-Rezeptorliganden, zur Prophylaxe und/oder Behandlung von Erkrankungen bereitgestellt, insbesondere von kardiovaskulären Erkrankungen; Erkrankungen des Urogenitalbereichs; Erkrankungen der Atemwege; inflammatorischen und neuroinflammatorischen Erkrankungen; Diabetes, insbesondere Diabetes mellitus; neurodegenerativen Erkrankungen; Schmerzzuständen; Krebs; sowie Leberfibrose und Leberzirrhose.

WO 01/25210 A2